SCHEMBL6017283

SCHEMBL6017283

COC(=O)c1ccnc(CN2CCN(CC(=O)NCC(=O)OC(C)(C)C)CCN(CC(=O)NCC(=O)OC(C)(C)C)CCN(CC(=O)NCC(=O)OC(C)(C)C)CC2)c1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 10/20 0.42
▸ MEN1 O00255 4/20 0.42
▸ KMT2A Q03164 4/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ KDM5C P41229 2/20 0.42
▸ KDM4C Q9H3R0 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.39
▸ KDM6B O15054 1/20 0.39
▸ KDM2A Q9Y2K7 1/20 0.39
▸ KDM3A Q9Y4C1 1/20 0.39
▸ TSHR P16473 4/20 0.39
▸ JMJD6 Q6NYC1 1/20 0.38
▸ MAPT P10636 2/20 0.37
▸ TP53 P04637 1/20 0.37
▸ LMNA P02545 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6017370 0.88 ALDH1A1 (0.47) ALDH1A1MEN1KMT2ASMN1; SMN2HSD17B10
SCHEMBL9736097 0.78 KDM4C (0.54) ALDH1A1MEN1KMT2ASMN1; SMN2HSD17B10
SCHEMBL1287025 0.75 KDM5C (0.51) ALDH1A1KMT2ASMN1; SMN2HSD17B10KDM5C
SCHEMBL15693171 0.75 HRH3 (0.41) ALDH1A1MEN1KMT2ASMN1; SMN2HSD17B10
SCHEMBL17155190 0.74 KDM5C (0.40) ALDH1A1MEN1KMT2AKDM5CKDM4C
SCHEMBL8183645 0.72 SIGMAR1 (0.43) ALDH1A1MEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL12682404 0.71 ATR (0.47) SMN1; SMN2KDM5CKDM4CKDM4EKDM6B
SCHEMBL31133034 0.71 ATR (0.47) SMN1; SMN2KDM5CKDM4CKDM4EKDM6B
SCHEMBL18406809 0.71 ALDH1A1 (0.39) ALDH1A1MEN1KMT2ASMN1; SMN2KDM5C
SCHEMBL1287113 0.70 NPC1 (0.45) MEN1KMT2ASMN1; SMN2KDM5CKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060275217-A1 Chemical exchange saturation transfer contrast agents EPIX PHARMACEUTICALS, INC. 2006-12-07 — — US disclosed
WO-2006121889-A2 CHEMICAL EXCHANGE SATURATION TRANSFER CONTRAST AGENTS EPIX PHARMACEUTICALS, INC. (US) 2006-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060275217-A1 Chemical exchange saturation transfer contrast agents SLC39A11, SLC30A7, SLC39A7 ALDH1A1 4811/4885MEN1 558/4885KMT2A 850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback